Human folate receptor ␣ (FR␣) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes. To study the possible use of this antigen in DNA vaccination, FR␣ cDNA was ligated into the VR1012 (Vical) expression vector under the transcriptional control of the cytomegalovirus promoter. A total of 100 g of purified plasmid DNA was injected intramuscularly in BALB/c mice three times at 14-day intervals. At 10 days after the second injection, the sera of the animals (100%) displayed significant antibody titers (by indirect immunofluorescence and fluorescence-activated cell sorter analysis) against syngeneic C26 cells transduced with FR␣, but not against unmodified C26 cells. Immunoglobulin G2a was the predominant isotype. In addition, specific cytotoxic T lymphocyte activity against FR␣-transduced C26 cells could be detected in splenocytes from all immunized animals. Coinjection of a plasmid containing interleukin-2 cDNA increased both antibody titers and cytotoxic T lymphocyte activity. Challenge by subcutaneous injection with FR␣-transduced C26 cells (performed 10 days after the third injection) showed a statistically significant delay in tumor growth. Vaccination with the FR␣ and interleukin-2 cDNA mixture, which was performed after an intravenous injection of FR␣-transduced cells, enhanced the mean survival time and reduced the number of lung metastases, thus suggesting that such vaccination is effective even against preexisting tumor cells.
T he demonstration that the injection of naked plasmid DNA into the muscle results in gene expression and immune response against the encoded protein has provided a new tool for vaccination strategies. [1] [2] [3] [4] In this approach, the gene is contained within an expression cassette and induces mRNA and protein synthesis directly into target cells in vivo, 5 thus allowing antigen (Ag) processing by the proteasome and the presentation of antigenic peptides by the major histocompatibility complex (MHC) class I pathway to cytotoxic T lymphocytes (CTLs). 6 In addition, DNA vaccination has been reported to induce Ag processing by professional Agpresenting cells and presentation by the MHC class II pathway to T helper (Th) cells. 6 Dendritic cells may either uptake the Ag released by other cells or may be directly transfected by the plasmid in the target organ or in the draining lymph nodes. 3 Naked DNA immunization induces a Th1 immune response that is mediated by the interleukin-2 (IL-2) and interferon-␥ (IFN-␥) secreted by Th1 cells, 7 resulting both in CTLs and in a predominantly immunoglobulin G2a (IgG2a) antibody (Ab) response. In view of these properties, DNA vaccination has been regarded as a promising tool to induce immunization against the antigenic proteins encoded by intracellular parasites, 8 -10 such as viruses, 4, [11] [12] [13] or against Ags preferentially expressed by tumor cells. 14 -16 Indeed, animal models have shown that DNA vaccination is capable of inducing a specific protective immunity against viral 13 or neoplastic cell challenge. 14, 16 Ags that are truly tumor-specific are uncommon, particularly in the case of epithelial tumors. Nutrients and growth factor receptors, albeit not entirely tumorspecific, have been considered to be suitable target molecules on such tumors due to their homogeneous and restricted pattern of overexpression. 17 The ␣ isoform of the folate receptor (FR), a 38-to 40-kDa glycosylphosphatidylinositol-anchored molecule, 18 -20 is expressed at very low levels on the cell surface of normal epithelial tissues; at medium levels on the kidney, lung, and breast; and at high levels on placental tissue. [21] [22] [23] Overexpression of FR␣ has been detected on ϳ90% of ovarian carcinomas 23, 24 in association with the progression of the disease, 25 on epithelial tumors derived from the uterus, and on nervous system tumors. 22 Based on its expression pattern, FR␣ has been used as a target molecule for monoclonal Ab (mAb)-based immunotherapy strategies. In a radioimmunotherapeutic trial, 5 of 16 ovarian carcinoma patients showed a complete response after intraperitoneal radioimmunotherapy with 131 I-labeled anti-FR␣ MOv18. 26 In addition, a clinical phase I/II trial of T-cell retargeting by bispecific anti-CD3/anti-FR␣ mAb showed tumor regression in 27% of ovarian carcinoma patients at advanced stages of the disease. 27 Limitations of this approach included activity restricted to the peritoneal cavity and the need for in vitro preactivation of the effector cells, thus limiting the routine application of this procedure. Moreover, no adverse events have been recorded in this previous experience, despite the moderate MOv18 reactivity on the renal tissue.
In this study, we have analyzed the possibility of inducing an immune response against FR␣ by DNA immunization. To this end, we have assembled a cytomegalovirus promoter expression vector containing human FR␣ cDNA, and we have evaluated its ability to induce an immune response by intramuscular (i.m.) injection into mice. We have detected both Ab and CTL FR␣-specific responses, which significantly reduced the "in vivo" growth of a syngeneic tumor transduced with FR␣ cDNA. In addition, we have evaluated the possible adjuvant effect of IL-2 cDNA coinjection.
MATERIALS AND METHODS

Vector construction
Plasmid VR1012/FR␣ was constructed by cloning a 900-base pair (bp) (EcoRV/XbaI) cDNA fragment containing the complete coding region of human FR␣ from pBS.#31. 19 The ability of VR1012/FR␣ to induce the expression of FR␣ was confirmed by indirect immunofluorescence staining of Chinese hamster ovary cells that had been transiently transfected by electroporation.
Human IL-2 cDNA (567 bp) was subcloned from RSV0.5neo/IL-2 28 in VR1012 (SalI/BamHI). COS-7 cells were transiently transfected by a standard diethylaminoethyl/dextran chloroquine method. The biological activity of the IL-2 secreted by the VR1012/IL-2-transfected COS-7 cells was determined in cell supernatants using a standard in vitro CTLL-2 proliferation assay.
DNA vaccination
Plasmid DNA was propagated in Escherichia coli DH1 bacteria using kanamycin selection and purified by an anion exchange resin system (Genomed, Bad Oeynhausen, Germany). Purified plasmid DNA was stored at Ϫ20°C at a concentration of 1 or 2 mg/mL before injection.
The animals used for these studies were 4-week-old female BALB/c mice (Harlan Nossan, Udine, Italy); mice were cared for according to the provisions of European Economic Community Council directive 86/209 (recognized and adopted by the Italian Government). A total of 100 g of purified DNA of VR1012/FR␣ (alone or in combination with the same amount of VR1012/IL-2) in sterile phosphate-buffered saline was injected into the "tibialis anteriore" muscles of both hind legs of individual mice at 2-week intervals for a total of three injections. As negative controls, mice were not injected, were injected with VR1012 plasmid, or were injected with VR1012/ IL-2. The total volume of injection was 50 L for each site. Blood samples were collected from the infraorbital sinus in anesthetized animals at 10 days after the second injection.
Evaluation of Ab responses by immunofluorescence
The Ab titer of sera was analyzed by indirect immunofluorescence. FR␣-transduced C26 cells were stained with sera at various dilutions (1/10, 1/100, and 1/500) or with an anti-FR␣ mAb (MOv19) as a positive control. Phycoerythrin-conjugated goat anti-mouse Ig antiserum or isotype-specific antisera were used as second-step reagents. Samples were analyzed with a FACScan analyzer (Becton Dickinson, San Jose, Calif).
Assay for CTL activity
Spleens were aseptically removed at 10 days after the third immunization, and 2 ϫ 10 7 immune spleen cells were restimulated in vitro in mixed lymphocyte tumor cell cultures (MLTCs) for 5 days with 5 ϫ 10 5 FR␣-transduced tumor cells (irradiated at 25,000 rad). The medium used was RPMI 1640 containing 10% heat-inactivated fetal calf serum, 4 mM glutamine, 50 M ␤-mercaptoethanol, 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid, and antibiotics.
The cytolytic activity of the lymphoblasts from MLTCs was measured in a standard 51 Cr release assay against syngeneic C26 cells (transduced with LXSN vector bearing the FR␣ cDNA or mock transduced).
51 Cr-labeled targets were mixed at appropriate ratios with restimulated effectors in triplicate wells of 96-well, V-bottom microtiter trays. After incubation at 37°C for 4 hours, 100 L of supernatant was collected from each well and counted in a gamma counter for the determination of 51 Cr release. The percentage of lysis was determined according to the following formula: ([sample release Ϫ spontaneous release]/ [total release Ϫ spontaneous release]) ϫ 100.
For the mAb inhibition experiments, 50 L of mAb solution (8 g/mL) in complete medium was added to 50 L of target cells in microtiter wells 10 minutes before the addition of effector cells in 100 L. The mAbs used in this assay were all IgG2a isotypes: MOv19 (anti-FR␣), 34.1.2S (anti-H2 d ) (kindly provided by Dr. R. S. Accolla, Centro di Biotecnologie Avanzate, Genova Italy), and ED6 (anti-hCD70, as irrelevant mAb).
Challenge with syngenic tumor cells expressing FR␣ transgene
At 14 days following the third injection, mice were challenged with a subcutaneous (s.c.) inoculation of 10 5 syngeneic transduced tumor cells. The size of the tumor was measured with a caliper every 3 days, and data were recorded as multiples of the wider and smaller tumor diameters.
Analysis of FR␣ mRNA and protein expression on tumor cells after challenge
The tumor fragments obtained from euthanized challenged animals were mechanically disaggregated. Recovered tumor cells were stained with MOv19 mAb and analyzed by indirect immunofluorescence. Total RNA was extracted from the cells by the RNAzol method (Cinna; Biotecx, Houston, Tex), and cDNA was obtained by reverse transcriptase reaction using oligo(dT) priming. A total of 2 L of cDNA was amplified by polymerase chain reaction (PCR) in the presence of 1 M of either primer, 1 mM of deoxynucleoside triphosphate, 10ϫ PCR buffer, and 1 U of AmpliTaq polymerase in a final volume of 25 L. The following primers were used: upper, 5Ј-GACA-GACATGGCTCAGCG; lower, 5Ј-GAACCTCGCCACCTC-CTC (amplifying a 691-bp fragment). Amplification was performed in a Perkin Elmer 2400 DNA thermal cycler (Perkin Elmer, Foster City, Calif) for 30 cycles (30 seconds at 94°C, 30 seconds at 57°C, and 45 seconds at 72°C) with a final extension at 72°C for 7 minutes. Amplified products (10 L) were analyzed on 1.5% agarose gels and stained with ethidium bromide.
RESULTS
Assembly and functional assessment of vectors
Human FR␣ 19 or IL-2 cDNAs 28 were assembled into the VR1012 expression plasmid (Vical, San Diego, Calif) under the transcriptional control of cytomegalovirus promoter and enhancer as depicted in Figure 1 . The resulting plasmids (VR1012/FR␣ and VR1012/IL-2) were assessed for their ability to drive protein synthesis by transient transfection on Chinese hamster ovary cells (for FR␣) or COS-7 cells (for IL-2) using electroporation. Cell staining at 48 hours after VR1012/FR␣ transfection by the anti-FR␣ mAb MOv19 24 revealed a bimodal distribution of immunofluorescence, identifying a population of ϳ25% of FR␣-expressing cells that was not detected in mock-transfected cells (data not shown). The supernatant of COS-7 cells transfected with VR1012/IL-2 showed the presence of biologically active IL-2 (80 -150 U/mL) as detected by the CTLL-2 proliferation assay (data not shown). These data indicated that both constructs were functional and capable of inducing expression of the encoded Ag or cytokine protein.
Analysis of Ab responses induced by i.m. injection of VR1012/FR␣ alone or coinjected with VR1012/IL-2 Sera from animals injected with naked VR1012/FR␣ plasmid (100 g) alone or in combination with VR1012/ IL-2 were obtained 10 days after the second injection and were tested by indirect immunofluorescence on FR␣-transduced syngeneic C26 cells. As shown in Figure  2 , these cells were brightly stained by the MOv19 anti-FR␣ mAb and were regarded as experimental controls. All sera from VR1012/FR␣-immunized animals showed significant staining of FR␣-transduced syngeneic C26 tumors at a 1/100 dilution (2 of 10 representative animals tested are shown in Fig 2, middle panels) . However, titers were higher in animals that had been coinjected with VR1012/IL-2, because reactivity was only detectable in coinjected animals at a 1/500 dilution of sera (average mean fluorescence intensity was 19 Ϯ 2 in coinjected animals versus 7 Ϯ 2 in animals immunized with VR1012/FR␣ alone). No significant staining was observed in the 1/10 diluted sera of untreated animals or of animals injected with VR1012 without cDNA or with VR1012/IL-2 (Fig 2, upper right panels) . The FR␣ specificity of sera from immunized animals was demonstrated by the lack of staining of untransduced or mock-transduced C26 cells (data not shown). The predominant Ig isotype was IgG2a, with a lower level of IgG1 and IgG2b components and undetectable IgM in both VR1012/FR␣-or VR1012/FR␣ plus VR1012/IL-2-immunized animals (the data of one representative VR1012/FR␣-immunized animal are shown in Fig 3) .
Induction of CTL activity in splenocytes from immunized animals Spleen cells obtained from immunized or control animals were activated in MLTCs for 5-6 days with irradiated FR␣-transduced C26 cells and subsequently tested for their ability to lyse 51 Cr-labeled mock-transduced or FR␣-transduced C26 cells. As shown in Figure 4B , T lymphoblasts from VR1012/FR␣-immunized animals developed CTL activity against FR␣-transduced C26 cells. Lymphoblasts from animals that had been coinjected with VR1012/IL-2 displayed higher levels of cytolysis. In contrast, no significant cytolytic activity against FR␣-transduced C26 cells was displayed by blasts obtained from untreated animals, from VR1012-injected control animals (data not shown), or from animals injected with VR1012 containing an irrelevant gene (MAGE-3).
The finding that blasts from immunized animals failed to lyse mock-transduced C26 cells indicated a specificity of recognition for the FR␣ Ag (Fig 4A) . In addition, the cytolysis of FR␣-transduced C26 cells, which was medi- ated by blasts from immunized animals, was not significantly modified by anti-FR␣ mAb or by an irrelevant mAb, but was inhibited by an anti-H2 d -specific mAb ( Fig  5) . Taken together, these data indicate that VR1012/ FR␣ vaccination induces FR␣-specific CTLs recognizing processed FR␣ peptide(s) presented by MHC class I molecules.
Challenge of immunized mice with FR␣-transduced C26 tumor
To further investigate whether DNA immunization could also result in a protective effect against tumors expressing FR␣ in vivo, we challenged immunized and control animals by a s.c. injection of FR␣-transduced C26 cells. Two separate experiments showed a statistically significant delay (P Ͻ .001) in tumor growth in animals that had been immunized with either VR1012/ FR␣ alone or in conjunction with VR1012/IL-2 compared with control groups (Fig 6) . A slightly more pronounced delay was observed in animals coinjected with VR1012/IL-2 with respect to the group injected with VR1012/FR␣ only (P ϭ not significant). Nevertheless, when tumors started to grow in vaccinated animals (after ϳ12 days of delay with respect to control animals), the tumor growth kinetics were similar to those of control animals. This finding suggested that delayed tumor growth in immunized animals could be associated with FR␣ Ag loss in tumor cells. To test this hypothesis, we examined the tumors recovered from immunized or control animals for FR␣ Ag expression. In all five of the tumors tested from immunized animals, no surface expression of FR␣ Ag could be detected, whereas FR␣ was maintained in a significant proportion of cells from the tumors recovered from control animals (Fig 7A) . An analysis of FR␣ mRNA showed that the loss of surface FR␣ Ag was related to a decreased expression of FR␣ mRNA (Fig 7B) , which was possibly related to in vivo long terminal repeat promoter shutdown and to the subsequent selection of Ag-negative cells by immune system pressure.
Therapeutic effect of FR␣ and IL-2 cDNA coinjection on development of lung metastases To verify the possible effects of DNA vaccination on preexisting tumor cells in vivo, we injected BALB/c mice intravenously with 7.5 ϫ 10 4 FR␣-transduced C26 cells. After 1 hour, groups of animals were injected i.m. with VR1012/IL-2 and VR1012/FR␣ either alone or in combination; the same treatment was repeated after 5 days. As shown in Figure 8 , mice receiving VR1012/IL-2 or VR1012/FR␣ displayed a mean survival time that was similar to that of control animals (15.6 Ϯ 0.5 or 16.4 Ϯ 1, respectively, versus 15.8 Ϯ 0.8), whereas mice treated with the combination of VR1012/IL-2 and VR1012/FR␣ showed a significantly prolonged mean survival time (25.4 Ϯ 0.9). The tumor cells recovered from the late metastases of animals immunized with the IL-2 and Ag cDNA combination completely lost their expression of FR␣ (data not shown). Moreover, the number of lung metastases in additional groups of animals receiving the combination of VR1012/IL-2 plus VR1012/FR␣ (sacrificed after day 13) was significantly lower (23 Ϯ 8.5) compared with control animals (175 Ϯ 35). Taken together, these data indicate that the IL-2 and Ag cDNA coinjection is capable of inducing a prompt and effective antitumor immune response against preexisting tumor cells in vivo.
DISCUSSION
In this study, we show that an i.m. vaccination with naked plasmid containing human FR␣ tumor-associated Ag (TAA) cDNA is efficient in inducing both Ab and CTL responses in mice. Such an immune response is able to control the in vivo growth of syngeneic tumor cells transduced with human FR␣.
FR␣ has been defined previously as an ovarian carcinoma TAA by means of specific mAbs raised in the mouse, and has been used as a target molecule for Ab-driven or bispecific Ab-redirected T-cell immunotherapy in humans. In addition, a recent study based on the search of human histocompatibility leukocyte Ag (HLA)-binding motifs by theoretical methods showed that multiple peptide sequences are present in this Ag, which may bind to different HLA class I alleles and may thus represent potential CTL epitopes. 29 Nevertheless, although several reports have indicated the possibility of raising HLA class I restricted CTLs against ovarian carcinoma cells, 30 and some of the Ags involved have been identified, 31 no proof of the existence of FR␣-specific CTLs has been provided thus far in humans. The possibility of inducing CTL activity in mice by genetic immunization indicates that the FR␣ Ag can be processed and presented to CTLs in murine cells through the MHC class I pathway, and opens new perspectives for inducing T-cell responses against ovarian carcinoma in humans.
These data are in keeping with previous reports of genetic immunization in mice using human TAA such as carcinoembryonic Ag 15 and chorionic ␤ gonadotropin, 32 which also showed an induction of murine Ag-specific CTLs or of T-cell proliferation in response to TAA and protection against challenge with syngeneic tumors expressing TAA.
It should be noted that successful vaccination against a heterologous Ag may not necessarily reflect the possibility of inducing an immune response against the corresponding "self" Ag. However, a recent report indicated that genetic immunization with the P1A gene, encoding for the P815A mastocytoma Ag, induces potent CTL responses, resulting in protection against P815 tumor challenge. 16 The P1A gene resembles the expression pattern of certain human TAAs, such as those belonging to the MAGE, BAGE, and GAGE families, which are expressed only in the placenta and testis. It is of note that MAGE-specific CTL responses can be induced in vivo in patients through vaccination with specific peptides. 33, 34 Because FR␣ also displays limited tissue expression in both humans and mice, it is thus conceivable that only a low degree of tolerance may exist with respect to this Ag.
In addition, it is known that immunization against heterologous proteins may induce immune reactions against the corresponding self homolog due to the existence of shared epitopes. In this context, a recent report indicates that DNA vaccination in mice against the human melanoma Ag glycoprotein 100 is capable of inducing cross-reactive CTLs recognizing a conserved epitope of the corresponding murine molecule. 35 In view of the good degree of homology (ϳ80% at the amino acid level) between human FR␣ and its murine equivalent, FBP-1, 36 it may be possible to induce similar cross-reactive immune responses.
Concerning the possibility of inducing unwanted reactions against normal tissues expressing low levels of FR␣, it should be noted that: (a) the level of expression in tumor cells is generally from 10-to 100-fold higher; (b) the normal tissues have a highly polarized (apical surface) localization of FR␣; and (c) no significant organ-specific toxicity has been observed in previous clinical studies employing anti-FR␣ mAbs or targeted T cells. In addition, other human TAAs, which are regarded as potential targets for vaccination strategies, such as carcinoembryonic Ag, are also expressed in some normal tissues.
Recent studies have shown that it is possible to boost immune responses to the foreign Ags encoded by naked plasmid DNA by the simultaneous coinjection of plasmids encoding for either costimulatory molecules (B7-1) 37 or cytokines such as IL-12 38 or GM-CSF. 39 IL-12 has been regarded as a molecular adjuvant in light of its ability to drive Th cell differentiation toward Th1. 38 Recent data indicate that the induction of Th1 responses by plasmid DNA is related to the presence of immunostimulatory DNA sequences, containing unmethylated CpG motifs 40 that activate natural immunity effector cells to secrete IFN-␥ and IL-12. 41 In the present study, we have exploited the possibility of boosting the immune response by the direct coinjection of IL-2 cDNA, which is, together with IFN-␥, the prototypic cytokine produced by Th1 cells. 42 Human FR␣ alone behaved as a "strong" Ag by DNA immunization, producing responses in 100% of the animals tested. Nevertheless, our present data suggest that IL-2 cDNA coinjection may represent a potentially active adjuvant to potentiate both Ab and CTL responses. More importantly, only the coinjection of IL-2 and FR␣ Ag cDNA is capable of inducing an antitumor effect in a metastasis model, where tumor cells were injected shortly before DNA immunization. The finding that an injection of VR1012/FR␣ alone was unable to produce significant antimetastatic effects suggests that the coinjection of IL-2 cDNA induces a more rapid immune response, which is required to a achieve an effect on preexisting neoplastic cells in an "aggressive" tumor model, such as C26.
These data also suggest that IL-2 cDNA coinjection may be useful in achieving a more rapid immune response in an immunotherapy setting and may eventually contribute to overcome the tolerant/immunosuppressed status of ovarian cancer patients. The development of bicistronic vectors containing both adjuvant cytokine (IL-2) and Ag cDNA may allow a better enhancement of the immune response and may reduce the amount of DNA to be prepared and injected.
We have been able to detect significant growth retardation of an FR␣-transduced syngeneic tumor. The finding that tumors growing in previously vaccinated mice lost FR␣ Ag expression is strongly suggestive of an efficient immune response in vivo, leading to the selection of Ag-negative variants. This could easily happen in our model, because the in vivo silencing of retroviral long terminal repeat promoters is a common phenomenon that is related to DNA methylation. The emergence of FR␣-negative cells, which were able to escape to the immune control of the host, was a peculiar limitation of the model used, but might not take place in humans. In fact, the FR␣ overexpression in human ovarian carcinomas seems to be an early event during the transformation process, and is maintained or even increased during tumor progression, suggesting that this molecule is essential for tumor cell life. 25 Moreover, no Ag loss variants could be detected in patients whose disease relapsed after passive immunotherapy with anti-FR␣ mAb 26 or after adoptive transfer of lymphocytes retargeted with anti-FR␣/anti-CD3 bispecific mAb. 27 In conclusion, our data indicate that human FR␣ DNA vaccination is effective in mice and may deserve further investigations to evaluate its possible application for immunotherapy of human ovarian cancer.
